18454701. COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA simplified abstract (THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE)
Contents
- 1 COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.9.1 Unanswered Questions
- 1.9.2 How does the modified human CBS compare to other enzyme replacement therapies currently available for homocystinuria treatment?
- 1.9.3 What are the potential long-term effects and risks associated with using modified human CBS for enzyme replacement therapy in patients with homocystinuria?
- 1.10 Original Abstract Submitted
COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA
Organization Name
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Inventor(s)
Jan P. Kraus of Denver CO (US)
Tomas Majtan of Aurora CO (US)
Erez Bublil of Ets Efraim (IL)
COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA - A simplified explanation of the abstract
This abstract first appeared for US patent application 18454701 titled 'COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA
Simplified Explanation
The patent application discusses compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
- Enzyme replacement therapy using modified human CBS for treating homocystinuria and related diseases and disorders.
- The modified human CBS can effectively replace the deficient enzyme in patients with homocystinuria.
- The therapy aims to alleviate symptoms and improve the quality of life for individuals with homocystinuria.
- The method involves administering the modified human CBS to patients in need of enzyme replacement therapy.
Potential Applications
The technology can be applied in the treatment of homocystinuria and related diseases and disorders where enzyme replacement therapy is required.
Problems Solved
This technology addresses the deficiency of cystathionine beta synthase in patients with homocystinuria, providing a potential solution for managing the condition.
Benefits
- Improved treatment options for individuals with homocystinuria - Potential to reduce symptoms and improve quality of life - Enhanced enzyme replacement therapy using modified human CBS
Potential Commercial Applications
Enzyme replacement therapy using modified human CBS could have commercial applications in the pharmaceutical industry for the treatment of homocystinuria and related disorders.
Possible Prior Art
Prior art may include existing enzyme replacement therapies for other genetic disorders, as well as research on cystathionine beta synthase deficiency in homocystinuria patients.
Unanswered Questions
How does the modified human CBS compare to other enzyme replacement therapies currently available for homocystinuria treatment?
The article does not provide a direct comparison between the modified human CBS therapy and other enzyme replacement therapies for homocystinuria.
What are the potential long-term effects and risks associated with using modified human CBS for enzyme replacement therapy in patients with homocystinuria?
The potential long-term effects and risks of using modified human CBS for enzyme replacement therapy are not discussed in detail in the article.
Original Abstract Submitted
Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
